Payers

Megan Olsen, MPH, principal at Avalere, discusses the role that value assessments are expected to play in the future pricing of gene and cell therapies.

The most-read AJAC papers of 2021 analyze real-world programs to transform health care and provide insight into physician perspectives of health care and insurance.

Despite being the seventh adalimumab biosimilar approved in the United States, there are none on the market yet.

Readers were most interested in articles about cost of therapy, drug efficacy, and a unique case related to COVID-19.

This year’s most-read articles on Medicare covered topics including accountable care organizations, value-based payment, and star ratings.

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses value-based benefit design strategies for high-deductible health plans.

Key opinion leaders discuss the state of mental health in the US workforce, persistent unmet needs, and efforts to improve coverage and uptake of behavioral health services.

Although the pandemic continued to rule health care headlines, a few other stories were noteworthy in 2021 for the AJMC.com audience, including articles about a wider indication for the glucagon-like peptide-1 receptor agonist semaglutide and the heart failure drug Entresto.

This year’s most-read articles on pulmonary arterial hypertension (PAH) covered a range of topics, including nutrition, therapy switches, and patient education to improve treatment adherence. Improving patient outcomes is something they all had in common.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.

This year the United States only approved 2 biosimilars, but the FDA did grant interchangeable status to the first biosimilar.

Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.

Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.

Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.

Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.

Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.

Jeffrey Patton, MD, is the CEO of OneOncology, a national partnership of independent community oncologists based in Nashville, Tennessee. He is also executive chairman of the board, Tennessee Oncology, and a member of the board, Community Oncology Alliance.

Vertical integration of payers and pharmacy benefit managers (PBMs) took flight with the mergers of Aetna and CVS Health and of Cigna and ExpressScripts. Panelists at Patient-Centered Oncology Care® said the shift has filtered down to affect access at the practice level.

Today’s challenge, according to Microsoft's Iksha Herr, MS, is learning how to leverage artificial intelligence (AI) to process the waves of health care data and to drive insights that lead to better care delivery.

Elizabeth Kwo, MD, MBA, MPH, is the deputy chief clinical officer, Anthem Blue Cross Blue Shield, Boston, Massachusetts. Kwo is a faculty lecturer at Harvard Medical School and physician entrepreneur.

The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.

Under the expanded FDA label, up to 1.8 million individuals in the United States could be eligible for sacubitril/valsartan, and up to 180,000 worsening heart failure (HF) events could be prevented or postponed.

Stacy Courtnay is the community network chair for the Arthritis Foundation in Atlanta highlights a report that discusses how understanding patient experiences in RA can shift questions researchers ask.

Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.